"Bleeding stem cell transplantation technology is really amazing!"

Recently, the Department of Blood and lymphatic tumors of Shunde Hospital of Southern Medical University once again ushered in an exciting good news, suffering from the recurrence/refractory acute marrow leukemia. Rehabilitation. Recalling his treatment process, it can be said that he has gone through the unforgettable journey of the doctor and patients.

Truth: High -risk cure leukemia recurs during consolidation of chemotherapy

The 53 -year -old Liang Shuben lives a life of three generations of Tongtang, food and clothing, and rarely gets sick. He basically "zero -intersection" with the hospital, but encountered a clear thunderbolt at the beginning of the year -diagnosis of acute marrow leukemia. The complex chromosome nucleus is a type of leukemia with high risk cure and poor prognosis.

After the precise treatment plan was formulated by the Department of Blood and lymphatic tumor, the patient had been relieved by the treatment of bone marrow cytology through a course of treatment, and MRD turned overcast. This gratifying treatment effect made Liang Uncle's hope of life. However, the treatment process is not smooth sailing. Uncle Liang has recurred after the fourth course of consolidating chemotherapy, and once again combined with targeted drugs for induced chemotherapy. It has not achieved the ideal results. The review of leukemia cells is still as high as 20%.

Decoration: Implementation of saving hematopic hematopoietic stem cell transplantation

According to Uncle Liang's specific situation, considering that the probability of re -chemotherapy relief is not high, and as the number of chemotherapy increases, the patient's cardiopulmonary and kidney function is damaged, the risk of subsequent transplantation will greatly increase, and it may be fully lost; The technical technical difficulty of the transplantation of heterogeneous hematopoietic stem cell transplantation is very difficult to overcome the high -strength pre -treatment of chemotherapy, stem cell planting, stem cell planting, and severe infection, acute plant anti -host disease before the stem cell planting, and a little difficulty If you are not careful, you will lose.

Faced with such a difficult choice, Professor Bai Hai, the leader of the Department of Blood and lymphatic science, analyzed it objectively, calmly judged, and after fully communicating with patients and family members, he decided to implement saving hematopoietic stem cell transplantation, and applied the latest domestic research results MCBC As a pre -processing plan, the plan takes into account pre -treatment toxicity and anti -leukemia effects.

Praise: "The technology of hematopoietic stem cell transplantation is really amazing"

Under the leadership of Professor Bai Hai, the deputy chief physician of Xiong Dan and the chief physician of the chief physician of the hematopoietic stem cell transplantation group of the Department of Blood and lymphoma immediately launched the transplantation procedure, opened the green channel. With the help of the nurses of the transplantation group Go to the warehouse smoothly. According to the transplantation plan, fine cultivation, step by step, under the careful treatment and care of all medical staff, the patient transplantation process is very smooth, and there is no serious liver and kidney toxicity and uncontrollable acute rejection. On the 13th day, the patient was reconstructed by hematopoietic. On the 20th day after transplantation, the bone marrow leukemia cells were cleared, and MRD was negative. From the process to the results, they all handed over a satisfactory answer, and they were praised by Uncle Liang and his family members. "The original hematopoietic stem cell transplantation technology is really amazing, the effect is very good, and it is not as hard as outside rumors." Uncle Liang said with a smile after leaving the position.

In the future: superb technology, more hardware to benefit more patients with blood diseases

According to Professor Bai Hai, the leader of the Department of Blood and lymphoma, this case is acute marrow leukemia (MDS conversion, accompanied by PT53 gene mutations and complex chromosomes). It can benefit patients, the prognosis is extremely poor, and simply relying on chemotherapy cannot obtain satisfactory effect. At present, hematopoietic stem cell transplantation is the only way to cure and cure acute leukemia.

The treatment is very difficult to treat this therapy, and it is also a test of the ability of the hematopoietic stem cell transplantation team of our hospital. Fortunately, through all the medical staff, we worked hard and worked hard. We did not disappoint the trust of the patient and handed over a satisfactory transcript. It is believed that in the near future, the technical level of the Southern Medical University Shunde Hospital's hematopoietic stem cell transplantation team will become more and more superb, and will benefit more patients with blood diseases.

At present, in order to solve the problem of "one warehouse is difficult to find" for patients with a large demand for blood malignant tumor transplantation and lining up for a long time, our hospital has expanded the blueprint of the transplantation warehouse as early as 2019. With the progress of the project, blood and lymphoma tumors The Creative Hematoplastment Transplantation Center will be expanded to 8 transplant warehouses in early August this year, providing more opportunities for long -term high -quality survival for patients with malignant hematological diseases. The department team will continue to use high -level, high -quality medical services to benefit more more Patients with blood diseases.

- END -